Latest: FDA Approves New Biosimilar for Oncology Treatment

Advances in Alzheimer Disease Screening and Antibody Therapy at AAIC 2025: Eric Siemers, MD

by Neurology Live

13 September, 2025

0 Mins

The chief medical officer at Acumen Pharmaceuticals discussed the benefits of using the blood-based p-tau 217 biomarker to improve screening accuracy and reduce patient burden in AD. [WATCH TIME: 5 minutes]

Tags:

Author

Neurology Live

PA union seeks injunction against NHS England in bid to pause changes to the role

Zuranolone and Breastfeeding: Emerging Data and Clinical Implications

📢

300x250 Banner

Advances in Alzheimer Disease Screening and Antibody Therapy at AAIC 2025: Eric Siemers, MD

Tags:

Neurology Live

PA union seeks injunction against NHS England in bid to pause changes to the role

Zuranolone and Breastfeeding: Emerging Data and Clinical Implications

Recent Content

COPD Biologics: Early Treatment Insights

Antihypertensive Medication Guidelines

Juvenile Arthritis Care Transition